This site is intended for healthcare professionals
News

NEJM publishes Phase III ILLUMINATE-A trial of lumasiran to treat primary hyperoxaluria type 1.- Alnylam Pharma

Read time: 1 mins
Last updated:3rd Apr 2021
Published:3rd Apr 2021
Condition: Hyperoxaluria
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest